Karyopharm Therapeutics Inc.
KPTIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Karyopharm Therapeutics Inc. focuses on Biotechnology services and products. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company carries a $178.2M market cap, placing it firmly in the micro-cap category. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Market Cap
$178.2M
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
-1.61
EPS (TTM)
$-17.27
EPS (Fwd)
$-4.89
ROE
—
ROA
-40.6%
Cash
$90.8M
Total Debt
$303.2M
Free CF
-$24.3M
52W Change
102.2%
Annual Financials
Cash vs Debt
Where KPTI stands vs its 150-day and 200-day moving averages
As of the June 30, 2026 close, KPTI finished 29.19% above its 150-day moving average ($7.81) and 36.91% above its 200-day moving average ($7.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KPTI overbought or oversold?
At the June 30, 2026 close, KPTI's RSI(14) was 65.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $90.8M in cash, though total debt stands at $303.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$24.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been relatively flat, moving from $157.1M (2022) to $146.1M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KPTI.